Wegweisend. - SöDAK 2009

3 EPIDEmIOlOGIE / EPIDEMIOlOGy Abstract
• High Influence of Migration and Sex-Work on the Epidemiological Situation of STI in Vienna/Austria: Results of
the BORDERNET Sentinel-Surveillance
klaus Jansen, andreas gilsdorf, elfriede steffan, osamah hamouda, Viviane Bremer; Berlin
• Impact of 44 months cART-dispensing on HIV-care in rural south-central Tanzania
marcel stoeckle, erik mossdorf, geofrey mwaigomole, evarist Chiweka, Patience kibatala, Christoph hatz, manuel
Battegay; Basel, ifakara
• The influence of genotypic resistance testing on antiretroviral first-line treatment decision in the German HIV-1-
Seroconverter-Study-Group
Claudia houareau, Barbara Bartmeyer, Claudia kücherer, nadine spielmann, Christian kollan, Christina lindemann,
osamah hamouda, german serokonverter study group; Berlin
• Factors associated with adverse pregnancy outcome in HIV positive women: Evidence from the Swiss Mother
and Child HIV cohort study.
karoline aebi-Popp, louise Vilén, tracy glass, olav lapaire, irene hoesli, mother and Child hiV Cohort study; Basel,
Bern
• Self-reported history of STI and STI-related utilization of the German health care system by MSM
axel J. schmidt, ulrich marcus; Berlin
• The Spectrum of Malignancies in the Era of HAART
martin Vogel, oliver friedrich, tobias höller, Jan-Christian wasmuth, evrim anadol, Carolynne schwarze-Zander,
Bernd holleczek, Jürgen kurt rockstroh, ulrich spengler; Bonn, saarbrücken
• Increasing Prevalence of Syphilis in MSM with Known Date of HIV-Infection from the German HIV-1
Seroconverter Study
ulrich marcus, Claudia kücherer, axel J. schmidt, Barbara gunsenheimer-Bartmeyer, Christina lindemann, nadine
spielmann, osamah hamouda, german hiV-1 seroconverter study group; Berlin
• HBV genotype diversity in HIV/HBV co-infected patients in the Swiss HIV cohort
florian Bihl, gladys martinetti, Bruno ledergeber, sandrine estoppey Younes, rainer weber, Pietro Vernazza, manuel
Battegay, hans Jakob furrer, matthias Cavassini, Bernhard hirschel, enos Bernasconi, swiss hiV Cohort study;
geneva, Bellinzona, Zurich, lausanne, st. gallen, Basel, Bern, lausanne, lugano
4 KLINIK UND THERAPIE / CliniCal Therapy
4.1 NEuERE SuBSTANZKlASSEN / NEw SuBSTANCE ClASSES
PW5 • Switching to raltegravir in HIV-infected patients with well controlled viral load – efficacy and safety
stefan mauss, ana milincovic, florian Berger, Julia henke, guenther schmutz, Petra hegener, Dieter kuschak,
stephan schauseil, Jospe mallolas, amina Carlebach, axel müller, Peter gute; Düsseldorf, Barcelona, frankfurt
• HIV integrase inhibition – more complex that simply blocking one key viral enzyme function
séverine louvel, françois hamy, thomas kiimkait; Basel
POSTER WALKS
PW1, PW2, PW3: Donnerstag, 25. Juni 15.00 - 16.00 uhr
PW4, PW5, PW6: freitag, 26. Juni 15.00 - 16.00 uhr
Die Posterausstellung befindet sich in der halle 9.1.2.
Session A • New antiretroviral treatment options with integrase-inhibitors, CCR5-antagonists and second-generation-NNRTI
and combination Antiretroviral Therapy (cART) in the ClinSurv Cohort
Barbara Bartmeyer, kollan Christian, kühne andrea, osamah hamouda, studiengruppe klinische surveillance
Clinsurv; Berlin
• Final results from the Connect cohort confirm efficacy and safety of enfuvirtide in a „real life setting“
olaf Degen, gerd faetkenheuer, J. Bogner, s. Dupke, s. koeppe, P. gute, w. Becker, a. tappe, egbert wellmann,
hans-Juergen stellbrink; hamburg, köln, münchen, Berlin, frankfurt, grenzach wyhlen
• Treatment of HIV-infected patients with a HAART regimen containing Enfuvirtide and a “second generation”
protease inhibitor
thore lorenzen, irene walther, Johannes r. Bogner, Jan van lunzen, Christoph schuler, gerd fätkenheuer, Peter
gute, Carl-knut schewe, siegfried köppe, Dietmar schranz, heinz-august horst, albrecht stoehr, andreas
Plettenberg; hamburg, münchen, hamburg, Berlin, köln, frankfurt/m, kiel
P324
P325
P326
P327
P328
P329
P330
P331
Abstract
P400
P401
P402
P403
P404
39